Finanzen von Tiziana Life Sciences Ltd (TLSA)TLSATiziana Life Sciences Ltd

Evaluating the bottom line, Tiziana Life Sciences Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -780.60%, provide a clear picture of how effectively TLSA converts its operational activities into shareholder value.

In the context of the broader market, TLSA competes directly with industry leaders such as IMUX and VTVT. With a market capitalization of $78.95M, it holds a significant position in the sector. When comparing efficiency, TLSA's gross margin of N/A stands against IMUX's N/A and VTVT's 100.00%. Such benchmarking helps identify whether Tiziana Life Sciences Ltd is trading at a premium or discount relative to its financial performance.

The company has reported substantial losses, with a net income of -7,209,000 USD in Q1 2025 and -5,632,000 USD in Q3 2025. The current ratio has improved to 1.72, indicating better short-term financial health, but the overall financials remain concerning with a high debt to equity ratio of 2.69% in Q1 2025.